As part of our media relations efforts, we pitch and secure national and regional media coverage for our clients.
Veteran Psychedelics Attorney Launches New Venture Capital Firm
Why PR Is Essential For Emerging Industries
The Top Venture-Capital Investors in the Psychedelics Industry
Ketamine Meditation, Jungle Tripping and Modern-Day Shamans: Meet a ‘Psychedelic Concierge’
Cannabis & Psychedelic Attorney Dustin Robinson on Psychedelics for Mental Health Treatment
Unreleased Lamar Odom Documentary To Explore How Psychedelic Drugs Helped The Basketball Star
Ketamine Meditation, Jungle Tripping and Modern-Day Shamans: Meet a ‘Psychedelic Concierge’
Meditación con ketamina, viajes a la jungla y chamanes modernos: conoce a un “concierge psicodélico”
Investing In Magic Mushrooms? Lauderdale Investor Is Betting They’re The Next Big Pharma Play
Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week
10 Questions You Always Wanted to Ask a Psychedelic Lawyer
Florida Lawmaker Introducing Psilocybin Mushroom Legalization
Dustin ‘Mr. Cannabis Law’ Robinson, The Attorney Advocating For Psychedelics Reform In Florida
Magic Mushrooms: Dustin Robinson of Mr. Psychdelic Law on NBC Miami News
This Mail-Order Ketamine Company Claims to Help Fight Your Depression
A Wall Street Banker Who Made Millions in the Dot Com Boom Dropped It All To Become A ‘Psychedelics Concierge’ To The Stars. Now He Wants Everyone To Have Access To Ketamine.
Ketamine Is The Answer To Depression And Suicide, Says Mike ‘Zappy’ Zapolin
A Wall Street Banker Who Made Millions in the Dot Com Boom Dropped It All To Become A ‘Psychedelics Concierge’ To The Stars. Now He Wants Everyone To Have Access To Ketamine.
Meet the ‘Psychedelic Concierge’ to the Stars
Microdose Presents The Mushroom Conference: A Molecular Masterclass
Psychedelics Advocate, Investor Zappy Says 2021 Is ‘The Year To Invest In Plant Medicine’
American Entrepreneur Mike “Zappy” Zapolin Joins @Redlightholland Ceo Todd Shapiro @Iamtoddytickles To Talk Psychedelics
Venture capital firm Iter Investments bets next pharma fortune is in psychedelics
